Oxford spinouts took in $350m in Q4 and OUI saw strong demand for its consulting services on the back of its covid-19 vaccine success.
Oxford University Innovation (OUI), the tech transfer office for University of Oxford, has revealed that its spinout portfolio generated over £255m ($350m) of funding in the last quarter of 2020 over the course of 31 deals.
The TTO also added seven new companies to its portfolio over the period including five spinouts and two social ventures, with the latter launched under the university’s impact innovation programme.
OUI’s latest batch collectively raised £2.2m ($3m) over the course of the quarter, and the office also signed 57 licensing deals, as well as processing 27 patent filings and 81 asset disclosures.
The university’s credibility was further bolstered by the sanctioning of its covid-19 vaccine developed in collaboration with AstraZeneca, with the vaccine now approved for use in several markets, which OUI said had resulted in “exceptionally high” demand for its medical sciences consulting service.
